Home

Keyvisual giving

 

Link to COMPETE Clinical Trial

COMPETE.
Phase III Clinical Trial.

Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.

View details >>

Targeted Radionuclide Therapy for Cancer Treatment.

PRRT as treatment option for cancers like neuroendocrine tumors. See a practicing physician and two patients talking about their experience.

Watch the Video

ITM receives Pharma Trend Award 2018 "Most Innovative Product"

ITM Isotopen Technologien München AG (ITM), a specialized group of radiopharmaceutical companies, announced today that it has received the Pharma…

Read more

Press Releases

ITM and Merck sign Research Evaluation and Option Agreement to develop Folate Receptor Targeted Radionuclide Therapy

The companies to combine their technologies to develop novel theranostic radiopharmaceuticals.

Merck to supply folate derivatives for the preparation…

Read more

Press Releases

RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.

Houston (TX, USA) and Garching (Germany), July 26, 2018 – RadioMedix Inc. and ITM Isotopen Technologien München (ITM), a group of specialized…

Read more

Press Releases

View all news »

Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...

Join the ITM Team >>